Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 18/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.47 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.47 |
| ▸ | MARK3 | P27448 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567817 | 1.00 | LRRK2 (0.58) | LRRK2KCNH2BRSK1MARK3SCN5A | |
| SCHEMBL24394351 | 1.00 | LRRK2 (0.58) | LRRK2KCNH2BRSK1MARK3SCN5A | |
| SCHEMBL29568017 | 0.87 | LRRK2 (0.48) | LRRK2KCNH2BRSK1MARK3SCN5A | |
| SCHEMBL24394350 | 0.87 | LRRK2 (0.48) | LRRK2KCNH2BRSK1MARK3SCN5A | |
| SCHEMBL30424449 | 0.87 | LRRK2 (0.48) | LRRK2KCNH2BRSK1MARK3SCN5A | |
| SCHEMBL29568377 | 0.85 | LRRK2 (0.78) | LRRK2KCNH2BRSK1MARK3SCN5A | |
| SCHEMBL29567993 | 0.85 | LRRK2 (0.78) | LRRK2KCNH2BRSK1MARK3SCN5A | |
| SCHEMBL29567808 | 0.85 | LRRK2 (0.78) | LRRK2KCNH2BRSK1MARK3SCN5A | |
| SCHEMBL29567756 | 0.85 | LRRK2 (0.78) | LRRK2KCNH2BRSK1MARK3SCN5A | |
| SCHEMBL26965839 | 0.85 | LRRK2 (0.78) | LRRK2KCNH2BRSK1MARK3SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116390727-A | N-linked isoquinolinamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof | 默沙东有限责任公司 | 2023-07-04 | — | — | CN | disclosed |